Premium
Efficacy of proton pump inhibitors for cellular proliferation and apoptosis in Barrett's oesophagus with different mucin phenotypes
Author(s) -
AMANO Y.,
CHINUKI D.,
YUKI T.,
TAKAHASHI Y.,
ISHIMURA N.,
KAZUMORI H.,
KUSHIYAMA Y.,
KARIM RUMI M. A.,
ISHIHARA S.,
KINOSHITA Y.
Publication year - 2006
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2006.00024.x
Subject(s) - mucin , cyclooxygenase , phenotype , proton pump inhibitor , apoptosis , mucin 2 , medicine , gastroenterology , cancer research , cell growth , pathology , immunology , microbiology and biotechnology , biology , biochemistry , gene expression , enzyme , gene
Summary Background Controversy exists concerning the efficacy of acid suppressants in the regression of Barrett's oesophagus. Aim To evaluate the effect of proton pump inhibitors on cyclooxygenase‐2 expression, cellular proliferation and apoptosis in Barrett's oesophagus with different mucin phenotypes. Methods Four hundred and sixty‐six biopsy samples of Barrett's oesophagus from 358 non‐treatment patients and 81 from 61 chronic proton pump inhibitor users were immunohistochemically examined using anti‐cyclooxygenase‐2 protein, anti‐proliferating cell nuclear antigen and anti‐single stranded DNA antigens in both mucin phenotypes of Barrett's oesophagus. Results Prevalence of the cyclooxygenase‐2 expression pattern did not significantly differ between the non‐treatment and proton pump inhibitor users. In those using proton pump inhibitors, significant suppression of the proliferating cell nuclear antigen index was found in Barrett's oesophagus with the gastric‐predominant mucin phenotype, but not with the intestinal‐predominant mucin phenotype. Apoptosis indices in chronic proton pump inhibitor users did not significantly differ between the two mucin phenotypes. Conclusions Proton pump inhibitors suppress cellular proliferation in Barrett's oesophagus with the gastric‐predominant mucin phenotype but not in that with the intestinal‐predominant mucin phenotype. This finding may at least partly explain the ongoing controversy surrounding the notion that all cases of Barrett's oesophagus respond to acid‐suppressive therapy.